Android Apple

EMA accepts GSK's Blenrep MAA for multiple myeloma for review

By Yahoo! Finance   |   4 months ago
EMA accepts GSK's Blenrep MAA for multiple myeloma for review

EMA has accepted GSK's application for Blenrep to treat relapsed/refractory multiple myeloma. The ADC, used with BorDex or PomDex, showed improved progression-free survival in Phase III trials. GSK aims to redefine outcomes for multiple myeloma patients.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.